Australia's CSL, which earlier this year paused plans to put its CSL Seqirus vaccine division up for sale, has opened the doors to a new $1 billion cell-based influenza vaccine and antivenom ...

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount. CSL shares remain down 35.2% over the past year, impacted by concerns over vaccine sales and ...

Accusing CSL of a “disgraceful” approach to bargaining, the CSL Behring workers are taking the protected action as the company puts out a revised offer to workers following the voting down of a ...

Forget one of one: this particular BMW 3.0 CSL is, quite literally, the very first M race car, and it’s up for sale for presumably many dollars. The very first official BMW M project was the 3.0 CSL.

CSL's share price has declined by 35% in 2025, influenced by a challenging US healthcare industry and cautious growth prospects. Despite headwinds, UBS sees potential medium-term recovery, especially ...

Our fair value estimate is 30% higher than CSL's analyst price target of US$248 In this article we are going to estimate the intrinsic value of CSL Limited (ASX:CSL) by projecting its future cash ...

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

CSL Seqirus, the vaccine unit of Australian biotech CSL, has signed a pact to provide Saudi Arabia with cell-based influenza shots and help establish its production in-country. The move forms part of ...

SYDNEY, Oct 28 (Reuters) - Australian biotech CSL (CSL.AX), opens new tab has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...